

Supplementary Figure 1: Trajectories of anti-SARS-CoV-2 Spike protein (anti-S) IgG titres in individual patients following first and second doses of vaccine, stratified by disease subtype.




Figure legend: All figures are presented with a Log₁₀ scale on the y-axis.

**lower limit of assay, **upper limit of assay, HR-MDS High Risk MDS*

S1A: Line graph seroconversion rates in patients with no previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose) in all patients; in patients with AML or HR-MDS (**S1B**) and in patients with ALL (**S1C**)

S1D: Seroconversion rates in all patients with previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose); displayed as a line graph (**S1E**)

Supplementary Figure 2: Serological responses in patients with Acute leukaemia stratified by therapy




Figure legend: All figures are presented with a Log₁₀ scale on the y-axis.

*lower limit of assay, **upper limit of assay, HR-MDS High Risk MDS

S2A: Serological response following two doses of vaccine in AML/HR-MDS treated with venetoclax-based regimens and no evidence of previous SARS-CoV-2 infection

S2B: Serological response following two doses of vaccine in patients treated with Rituximab and non-Rituximab containing regimens: Median 342 U/mL (IQR 1.69-1541) vs Median 7.5U/mL (IQR 2.6-751.5) p=0.83

S2C: Serological response following two doses of vaccine in patients treated with Rituximab and non-rituximab containing regimens (Baseline COVID -ve only): Median 2.980 (IQR 0.4-342) vs Median 6.280 U/mL (IQR 3.7-239.7) p=0.6